Skip to main content
. 1999 Jun 22;96(13):7462–7466. doi: 10.1073/pnas.96.13.7462

Figure 1.

Figure 1

Schematic outline of trial design. During the initial period, while patients were receiving infusions of Daclizumab every 2 weeks, patients were tapered off their standard immunosuppressive therapy that they were receiving for treatment of uveitis.